Injectable solution containing a shark-derived chondroitin sulfate iron colloid

• US 20030118666A1
• Filed: 10/10/2002
• Published: 06/26/2003
• Est. Priority Date: 10/12/2001
• Status: Abandoned Application

• Current Assignee: Nipro Corporation
• Original Assignee: Nipro Corporation
• Inventors: Katayama, Naohisa, Sato, Makoto, Katsumata, Takashi, Nishida, Seiji
• Application Number:
  US10/267,848
• Publication Number:
  US 20030118666A1
• Time in Patent Office: Days
• US Class Current: 424/646
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 33/26 Iron; Compounds thereof
• CPC Class Codes: A61K 35/60 Fish, e.g. seahorses; Fish eggs
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/61 the organic macromolecular compound being a polysaccharide or a derivative thereof
• CPC Class Codes: A61K 47/6905 the form being a colloid or an emulsion
• CPC Class Codes: A61P 7/06 Antianaemics

Abstract

An injectable solution comprising a shark-derived chondroitin sulfate iron colloid, and a method for manufacturing an injectable solution comprising the step of adding an aqueous ferric salt solution and an aqueous alkali metal hydroxide solution to a shark-derived chondroitin sulfate solution, such that the resulting mixture has a pH value adjusted to any pH value within the range of from about 5.5 to about 7.5.

Claims

1. An injectable solution which comprises a shark-derived chondroitin sulfate iron colloid.

2. An injectable solution as claimed in claim 1, wherein the shark-derived chondroitin sulfate iron colloid is prepared from a shark-derived chondroitin sulfate.

3. An injectable solution as claimed in claim 2, wherein the shark-derived chondroitin sulfate is an alkali metal salt of shark-derived chondroitin sulfate.

4. An injectable solution as claimed in claim 2, wherein the shark-derived chondroitin sulfate is a shark-derived sodium chondroitin sulfate.

5. An injectable solution as claimed in claim 4, wherein the shark-derived sodium chondroitin sulfate has an average molecular weight of from about 10,000 to about 25,000, a limiting viscosity of from about 0.27 to about 0.65 dL/g, and a sulfur content of from about 6.4 to about 7.0 w/w %.

6. An injectable solution as claimed in claim 5, wherein the weight ratio of iron:

sodium chondroitin sulfate is 1;

7 or less.

7. An injectable solution as claimed in claim 1, wherein the shark-derived chondroitin sulfate iron colloid is produced by adding an aqueous ferric salt solution and an aqueous alkali metal hydroxide solution to an aqueous shark-derived chondroitin sulfate iron solution and maintaining the pH value of the resulting mixture in the range of from about 5.5 to about 7.5.

8. A method for manufacturing an injectable solution, which comprises adding an aqueous ferric salt solution and an aqueous alkali metal hydroxide salt solution to an aqueous shark-derived chondroitin sulfate solution and maintaining the pH value of the resulting mixture in the range of from about 5.5 to about 7.5.

9. A method for manufacturing an injectable solution, which comprises adding an aqueous ferric salt solution and an aqueous sodium hydroxide solution to a shark-derived sodium chondroitin sulfate solution and maintaining the pH value of the resulting mixture in the range of from about 5.5 to about 7.5.